Protagonist Therapeutics, Inc. (PTGX)
Last Price$38.4(1.8%)
Market Cap$2,361.1M
PTGX Rating
PTGX Quality rating performance
PTGX Intrinsic Value
Key Highlights:
As of Mar 07, 2025 PTGX Relative Value is $20.6, which is overvalued by 46.4%, compared to current share price of $38.4.
As of Mar 07, 2025 PTGX DCF Value is N/A, which is undervalued by N/A, compared to current share price of $38.4.
PTGX Share Price History
1W 2.0%
1M (1.4%)
6M (14.0%)
YTD 63.7%
1Y 24.2%
3Y 60.8%
5Y 410.0%
10Y 227.8%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
PTGX Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$2,361.1M
$1,953.0M
$434.4M
$182.8M
Shares Outstanding
62M
Employees
N/A
Growth (CAGR)
351.7%
N/A
422.2%
Profitability
99.6%
58.2%
63.3%
42.4%
42.1%
66.4%
Intrinsic Value
$20.6 (46.3% overvalued)
N/A
$20.6
($15.5)
($1,018.5)
113.7%
Return on Capital
Financial Health
($408.0M)
(2.2x)
Dividends
Earnings
May 05, 2025
MISS by (730.2%)
BEAT by (9.3%)
500.0%
7 Beat & 3 Miss
PTGX Stock Financials
PTGX Income Statement Metrics
Annual
Quarterly
LTM
PTGX Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($70.2M) -35.0% YoY
Capital Expenditure (CAPEX)
($609.0K) -23.4% YoY
Free Cash Flow (FCF)
($70.8M) -35.0% YoY
PTGX Income Statement Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
PTGX Balance Sheet Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$358.0M
Current assets ($355.6M, 99.3% of total)
$341.6M (95.4%)
$10.3M (2.9%)
Other current assets
$3,628.0K (1.0%)
Non-current assets ($2,374.0K, 0.7% of total)
$0.0 (0.0%)
$2,149.0K (0.6%)
$0.0 (0.0%)
Other non-current assets
$225.0K (0.1%)
Financial position
($340.5M)
Cash & Short-term
Investments
Total Debt
PTGX Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
PTGX Earnings Surprises
Crunching data... Almost there!
PTGX Dividends
PTGX Dividend Yield
Crunching data... Almost there!
PTGX Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with PTGX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$2,361.1M | 7.4 | $20.6 46.3% overvalued | 24.2% | $434.4M | $182.8M | 624.1% | 42.1% | 99.6% | 259.8% | 1.6% | |
$388.2B | 6.7 | $66.2 24.0% overvalued | (35.4%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$125.7B | 5.7 | $170.9 65.0% overvalued | 18.9% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$76.1B | 6.3 | $1,055.2 49.1% undervalued | (27.3%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$35.7B | 5.8 | $79.3 86.7% overvalued | 52.9% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$31.4B | 5.3 | $89.6 63.3% overvalued | 63.2% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$26.1B | 6.3 | $182.2 67.5% undervalued | 19.4% | €3,040.1M | €985.3M | (54.1%) | 32.4% | 84.3% | (41.4%) | 1.3% | |
$14.1B | 7.8 | $446.5 41.3% undervalued | 31.7% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.7B | 5.7 | $77.7 118.1% undervalued | (64.2%) | $3,229.0M | ($4,055.0M) | (52.9%) | (125.6%) | 52.3% | (98.9%) | 6.5% | |
$12.8B | 5.9 | $0.6 96.4% overvalued | 276.7% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.2 | $3,780.8 1,567.7% undervalued | 39.9% | $3,316.8M | ($1,009.2M) | 50.5% | (30.4%) | 83.1% | (38.4%) | 32.1% |
FAQ
What is Protagonist Therapeutics, Inc. (PTGX) stock rating?
As of today, Protagonist Therapeutics, Inc. has a stock rating of 7 (out of 10), which is considered Great.
is Protagonist Therapeutics, Inc. (PTGX) a good stock to buy?
As of today, Protagonist Therapeutics, Inc. has a Great stock rating, which is 46.3% overvalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 0.5%.